Strategies for designing and optimizing new generation vaccines (original) (raw)

• Berzofsky, J. A. et al. Approaches to improve engineered vaccines for human immunodeficiency virus (HIV) and other viruses that cause chronic infections. Immunol. Rev. 170, 151–172 (1999).
  Article CAS PubMed Google Scholar
• Berzofsky, J. A. Epitope selection and design of synthetic vaccines: molecular approaches to enhancing immunogenicity and crossreactivity of engineered vaccines. Ann. NY Acad. Sci. 690, 256–264 (1993).
  Article CAS PubMed Google Scholar
• Morgan, D. J., Kreuwel, H. T. & Sherman, L. A. Antigen concentration and precursor frequency determine the rate of CD8+ T cell tolerance to peripherally expressed antigens. J. Immunol. 163, 723–727 (1999).
  CAS PubMed Google Scholar
• Sandberg, J. K. et al. T cell tolerance based on avidity thresholds rather than complete deletion allows maintenance of maximal repertoire diversity. J. Immunol. 165, 25–33 (2000).
  Article CAS PubMed Google Scholar
• Pogue, R. R., Eron, J., Frelinger, J. A. & Matsui, M. Amino-terminal alteration of the HLA-A*0201-restricted human immunodeficiency virus pol peptide increases complex stability and in vitro immunogenicity. Proc. Natl Acad. Sci. USA 92, 8166–8170 (1995).
  Article CAS PubMed PubMed Central Google Scholar
• Sarobe, P. et al. Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions. J. Clin. Invest. 102, 1239–1248 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Parkhurst, M. R. et al. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J. Immunol. 157, 2539–2548 (1996).
  CAS PubMed Google Scholar
• Rosenberg, S. A. et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med. 4, 321–327 (1998).
  Article CAS PubMed Google Scholar
• Irvine, K. R. et al. Recombinant virus vaccination against 'self' antigens using anchor-fixed immunogens. Cancer Res. 59, 2536–2540 (1999).
  CAS PubMed PubMed Central Google Scholar
• Ahlers, J. D., Takeshita, T., Pendleton, C. D. & Berzofsky, J. A. Enhanced immunogenicity of HIV-1 vaccine construct by modification of the native peptide sequence. Proc. Natl Acad. Sci. USA 94, 10856–10861 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Ahlers, J. D., Belyakov, I. M., Thomas, E. K. & Berzofsky, J. A. High affinity T-helper epitope induces complementary helper and APC polarization, increased CTL and protection against viral infection. J. Clin. Invest. 108, 1677–1685 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Rammensee, H.-G., Friede, T. & Stevanovíc, S. MHC ligands and peptide motifs: first listing. Immunogenetics 41, 178–228 (1995).
  Article CAS PubMed Google Scholar
• Ruppert, J. et al. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 74, 929–937 (1993).
  Article CAS PubMed Google Scholar
• Alexander, J. et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1, 751–761 (1994).
  Article CAS PubMed Google Scholar
• La Rosa, C. et al. Enhanced immune activity of cytotoxic T-lymphocyte epitope analogs derived from positional scanning synthetic combinatorial libraries. Blood 97, 1776–1786 (2001).
  Article CAS PubMed Google Scholar
• Slansky, J. E. et al. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC–peptide–TCR complex. Immunity 13, 529–538 (2000).
  Article CAS PubMed Google Scholar
• Zaremba, S. et al. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res. 57, 4570–4577 (1997).
  CAS PubMed Google Scholar
• Fong, L. et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl Acad. Sci. USA 98, 8809–8814 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Tangri, S. et al. Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide. J. Exp. Med. 194, 833–846 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Takahashi, H. et al. Induction of broadly cross-reactive cytotoxic T cells recognizing an HIV-1 envelope determinant. Science 255, 333–336 (1992).
  Article CAS PubMed Google Scholar
• Alexander-Miller, M. A., Leggatt, G. R. & Berzofsky, J. A. Selective expansion of high or low avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc. Natl Acad. Sci. USA 93, 4102–4107 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Gallimore, A., Dumrese, T., Hengartner, H., Zinkernagel, R. M. & Rammensee, H. G. Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides. J. Exp. Med. 187, 1647–1657 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Zeh, H. J. III, Perry-Lalley, D., Dudley, M. E., Rosenberg, S. A. & Yang, J. C. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J. Immunol. 162, 989–994 (1999).
  CAS PubMed Google Scholar
• Yee, C., Savage, P. A., Lee, P. P., Davis, M. M. & Greenberg, P. D. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J. Immunol. 162, 2227–2234 (1999).
  CAS PubMed Google Scholar
• Derby, M. A., Wang, J., Margulies, D. H. & Berzofsky, J. A. Two intermediate avidity CTL clones with a disparity between functional avidity and MHC tetramer staining. Int. Immunol. 13, 817–824 (2001).
  Article CAS PubMed Google Scholar
• Slifka, M. K. & Whitton, J. L. Functional avidity maturation of CD8+ T cells without selection of higher affinity TCR. Nature Immunol. 2, 711–717 (2001).
  Article CAS Google Scholar
• Margulies, D. H. TCR avidity: it's not how strong you make it, it's how you make it strong. Nature Immunol. 2, 669–670 (2001).
  Article CAS Google Scholar
• Cawthon, A. G., Lu, H. & Alexander-Miller, M. A. Peptide requirement for CTL activation reflects the sensitivity to CD3 engagement: correlation with CD8αβ versus CD8αα expression. J. Immunol. 167, 2577–2584 (2001).
  Article CAS PubMed Google Scholar
• Fahmy, T. M., Bieler, J. G., Edidin, M. & Schneck, J. P. Increased TCR avidity after T cell activation. A mechanism for sensing low-density antigen. Immunity 14, 135–143 (2001).
  CAS PubMed Google Scholar
• Alexander-Miller, M. A., Leggatt, G. R., Sarin, A. & Berzofsky, J. A. Role of antigen, CD8, and cytotoxic T lymphocyte avidity in high dose antigen induction of apoptosis of effector CTL. J. Exp. Med. 184, 485–492 (1996).
  Article CAS PubMed Google Scholar
• Alexander-Miller, M. A., Derby, M. A., Sarin, A., Henkart, P. A. & Berzofsky, J. A. Supra-optimal peptide/MHC causes a decrease in Bcl-2 and allows TNF-α receptor II-mediated apoptosis of CTL. J. Exp. Med. 188, 1391–1399 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Zheng, L. et al. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 377, 348–351 (1995).
  Article CAS PubMed Google Scholar
• Derby, M. A., Alexander-Miller, M. A., Tse, R. & Berzofsky, J. A. High avidity CTL exploit two complementary mechanisms to provide better protection against viral infection than low avidity CTL. J. Immunol. 166, 1690–1697 (2001).
  Article CAS PubMed Google Scholar
• Kawamura, H., Rosenberg, S. A. & Berzofsky, J. A. Immunization with antigen and interleukin-2 in vivo overcomes Ir gene low responsiveness. J. Exp. Med. 162, 381–386 (1985).
  Article CAS PubMed Google Scholar
• Good, M. F. et al. Recombinant human interleukin-2 (IL-2) overcomes genetic nonresponsiveness to malaria sporozoite peptides. Correlation of effect with biological activity of IL-2. J. Immunol. 141, 972–977 (1988).
  CAS PubMed Google Scholar
• Ahlers, J. D., Dunlop, N., Alling, D. W., Nara, P. L. & Berzofsky, J. A. Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: GM-CSF and TNFα synergize with IL-12 to enhance induction of CTL. J. Immunol. 158, 3947–3958 (1997).
  CAS PubMed Google Scholar
• Disis, M. L. et al. Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood 88, 202–210 (1996).
  Article CAS PubMed Google Scholar
• Belyakov, I. M., Ahlers, J. D., Clements, J. D., Strober, W. & Berzofsky, J. A. Interplay of cytokines and adjuvants in the regulation of mucosal and systemic HIV-specific cytotoxic T lymphocytes. J. Immunol. 165, 6454–6462 (2000).
  Article CAS PubMed Google Scholar
• Xiang, Z. & Ertl, H. C. J. Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity 2, 129–135 (1995).
  Article CAS PubMed Google Scholar
• Kim, J. J. et al. Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens. Eur. J. Immunol. 28, 1089–1103 (1998).
  Article CAS PubMed Google Scholar
• Iwasaki, A., Stiernholm, B. J. N., Chan, A. K., Berinstein, N. L. & Barber, B. H. Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines. J. Immunol. 158, 4591–4601 (1997).
  CAS PubMed Google Scholar
• Scheerlinck, J. Y. Genetic adjuvants for DNA vaccines. Vaccine 19, 2647–2656 (2001).
  Article CAS PubMed Google Scholar
• Dranoff, G. et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl Acad. Sci. USA 90, 3539–3543 (1993).
  Article CAS PubMed PubMed Central Google Scholar
• Flexner, C., Hügin, A. & Moss, B. Prevention of vaccinia virus infection in immunodeficient mice by vector-directed IL-2 expression. Nature 330, 259–262 (1987).
  Article CAS PubMed Google Scholar
• Ramshaw, I. A., Andrew, M. E., Phillips, S. M., Boyle, D. B. & Coupar, B. E. Recovery of immunodeficient mice from a vaccinia virus/IL-2 recombinant infection. Nature 329, 545–546 (1987).
  Article CAS PubMed Google Scholar
• Barouch, D. H. et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290, 486–492 (2000).
  Article CAS PubMed Google Scholar
• Zhang, X., Sun, S., Hwang, I., Tough, D. F. & Sprent, J. Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. Immunity 8, 591–599 (1998).
  Article CAS PubMed Google Scholar
• Ku, C. C., Murakami, M., Sakamoto, A., Kappler, J. & Marrack, P. Control of homeostasis of CD8+ memory T cells by opposing cytokines. Science 288, 675–678 (2000).
  Article CAS PubMed Google Scholar
• Waldmann, T. A., Dubois, S. & Tagaya, Y. Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. Immunity 14, 105–110 (2001).
  CAS PubMed Google Scholar
• Xin, K. Q. et al. IL-15 expression plasmid enhances cell-mediated immunity induced by an HIV-1 DNA vaccine. Vaccine 17, 858–866 (1999).
  Article CAS PubMed Google Scholar
• Ahlers, J. D., Belyakov, I. M., Matsui, S. & Berzofsky, J. A. Mechanisms of cytokine synergy essential for vaccine protection against viral challenge. Int. Immunol. 13, 897–908 (2001).
  Article CAS PubMed Google Scholar
• Ahlers, J. D., Belyakov, I. M., Matsui, S. & Berzofsky, J. A. Signals delivered through TCR instruct IL-12R expression: IL-12 and TNFα synergize for IL-12R expression at low antigen dose. Int. Immunol. 13, 1433–1442 (2001).
  Article CAS PubMed Google Scholar
• Chamberlain, R. S. et al. Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines. Cancer Res. 56, 2832–2836 (1996).
  CAS PubMed PubMed Central Google Scholar
• Freund, Y. R. et al. Vaccination with recombinant vaccinia vaccine containing the B7-1 co-stimulatory molecule causes no significant toxicity and enhances T cell-mediated cytotoxicity. Int. J. Cancer 85, 508–517 (2000).
  Article CAS PubMed Google Scholar
• Kim, J. J. et al. Development of a multicomponent candidate vaccine for HIV-1. Vaccine 15, 879–883 (1997).
  Article CAS PubMed Google Scholar
• Rao, J. B. et al. IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression. J. Immunol. 156, 3357–3365 (1996).
  CAS PubMed Google Scholar
• Gurunathan, S. et al. CD40 ligand/trimer DNA enhances both humoral and cellular immune responses and induces protective immunity to infectious and tumor challenge. J. Immunol. 161, 4563–4571 (1998).
  CAS PubMed Google Scholar
• Sin, J. I., Kim, J. J., Zhang, D. & Weiner, D. B. Modulation of cellular responses by plasmid CD40L: CD40L plasmid vectors enhance antigen-specific helper T cell type 1 CD4+ T cell-mediated protective immunity against herpes simplex virus type 2 in vivo. Hum. Gene Ther. 12, 1091–1102 (2001).
  Article CAS PubMed Google Scholar
• Hodge, J. W. et al. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res. 59, 5800–5807 (1999).
  CAS PubMed Google Scholar
• Zhu, M. et al. Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells. Cancer Res. 61, 3725–3734 (2001).
  CAS PubMed Google Scholar
• Veazey, R. S. & Lackner, A. A. The gastrointestinal tract and the pathogenesis of AIDS. AIDS 12, S35–S42 (1998).
  Article PubMed Google Scholar
• Baba, T. W. et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nature Med. 6, 200–206 (2000).
  Article CAS PubMed Google Scholar
• Mascola, J. R. et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nature Med. 6, 207–210 (2000).
  Article CAS PubMed Google Scholar
• Schmitz, J. E. et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283, 857–860 (1999).
  Article CAS PubMed Google Scholar
• Jin, X. et al. Dramatic rise in plasma viremia after CD8+ T cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med. 189, 991–998 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Kaul, R. et al. HIV-1-specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1-resistant prostitutes in nairobi. J. Immunol. 164, 1602–1611 (2000).
  Article CAS PubMed Google Scholar
• Belyakov, I. M. et al. Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge. Proc. Natl Acad. Sci. USA 95, 1709–1714 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Belyakov, I. M. et al. Induction of mucosal CTL response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing HIV 89.6 envelope protein. J. Virol. 72, 8264–8272 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Belyakov, I. M. et al. The importance of local mucosal HIV-specific CD8+ cytotoxic T lymphocytes for resistance to mucosal-viral transmission in mice and enhancement of resistance by local administration of IL-12. J. Clin. Invest. 102, 2072–2081 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Murphey-Corb, M. et al. Selective induction of protective MHC class I restricted CTL in the intestinal lamina propria of rhesus monkeys by transient SIV infection of the colonic mucosa. J. Immunol. 162, 540–549 (1999).
  CAS PubMed Google Scholar
• Eo, S. K., Gierynska, M., Kamar, A. A. & Rouse, B. T. Prime–boost immunization with DNA vaccine: mucosal route of administration changes the rules. J. Immunol. 166, 5473–5479 (2001).
  Article CAS PubMed Google Scholar
• Cromwell, M. A. et al. Induction of mucosal homing virus-specific CD8+ T lymphocytes by attenuated simian immunodeficiency virus. J. Virol. 74, 8762–8766 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Belyakov, I. M., Moss, B., Strober, W. & Berzofsky, J. A. Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. Proc. Natl Acad. Sci. USA 96, 4512–4517 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Veazey, R. S. et al. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science 280, 427–431 (1998).
  Article CAS PubMed Google Scholar
• Belyakov, I. M. et al. Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques. Nature Med. 7, 1320–1326 (2001).
  Article CAS PubMed Google Scholar
• Lehner, T. et al. Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques. Nature Med. 2, 767–775 (1996).
  Article CAS PubMed Google Scholar
• Lehner, T., Bergmeier, L., Wang, Y., Tao, L. & Mitchell, E. A rational basis for mucosal vaccination against HIV infection. Immunol. Rev. 170, 183–196 (1999).
  Article CAS PubMed Google Scholar
• Mestecky, J. & Fultz, P. N. Mucosal immune system of the human genital tract. J. Infect. Dis. 179 (Suppl. 3), S470–S474 (1999).
  Article PubMed Google Scholar
• Kozlowski, P. A., Cu-Uvin, S., Neutra, M. R. & Flanigan, T. P. Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women. Infect. Immun. 65, 1387–1394 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Lehner, T. et al. The effect of route of immunization on mucosal immunity and protection. J. Infect. Dis. 179 (Suppl. 3), S489–S492 (1999).
  Article PubMed Google Scholar
• Scharton-Kersten, T. et al. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants. Infect. Immun. 68, 5306–5313 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Dickinson, B. L. & Clements, J. D. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect. Immun. 63, 1617–1623 (1995).
  Article CAS PubMed PubMed Central Google Scholar
• Oliver, A. R. & Elson, C. O. Role of mucosal adjuvants in mucosal immunization. Curr. Opin. Gastroenterol. 14, 438–487 (1998).
  Google Scholar
• Pizza, M. et al. Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine 19, 2534–2541 (2001).
  Article CAS PubMed Google Scholar
• Czerkinsky, C. et al. Mucosal immunity and tolerance: relevance to vaccine development. Immunol. Rev. 170, 197–222 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Cheng, E., Cardenas-Freytag, L. & Clements, J. D. The role of cAMP in mucosal adjuvanticity of Escherichia coli heat-labile enterotoxin (LT). Vaccine 18, 38–49 (1999).
  Article CAS PubMed Google Scholar
• Braun, M. C., He, J., Wu, C.-Y. & Kelsall, B. L. Cholera toxin suppresses interleukin (IL)-12 production and IL-12 receptor B1 and B2 chain expression. J. Exp. Med. 189, 541–552 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Lehner, T. et al. The role of γδ T cells in generating antiviral factors and β-chemokines in protection against mucosal simian immunodeficiency virus infection. Eur. J. Immunol. 30, 2245–2256 (2000).
  Article CAS PubMed Google Scholar
• Gallichan, W. S. et al. Intranasal immunization with CpG oligodeoxynucleotides an as adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. J. Immunol. 166, 3451–3457 (2001).
  Article CAS PubMed Google Scholar
• Horner, A. A. et al. Immunostimulatory DNA-based vaccines elicit multifaceted immune responses against HIV at systemic and mucosal sites. J. Immunol. 167, 1584–1591 (2001).
  Article CAS PubMed Google Scholar
• Marinaro, M. et al. Oral but not parenteral interleukin (IL)-12 redirects T helper 2 (TH2)-type responses to an oral vaccine without altering mucosal IgA responses. J. Exp. Med. 185, 415–427 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Thornton, A. M. & Shevach, E. M. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. 188, 287–296 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Shimizu, J., Yamazaki, S. & Sakaguchi, S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163, 5211–5218 (1999).
  CAS PubMed Google Scholar
• Salomon, B. et al. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 12, 431–440 (2000).
  Article CAS PubMed Google Scholar
• Waldmann, H. & Cobbold, S. Regulating the immune response to transplants: a role for CD4+ regulatory cells? Immunity 14, 399–406 (2001).
  Article CAS PubMed Google Scholar
• Thornton, A. M. & Shevach, E. M. Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J. Immunol. 164, 183–190 (2000).
  Article CAS PubMed Google Scholar
• Terabe, M. et al. Negative regulation of CTL-mediated tumour immunosurveillance through NKT cell induced IL-13 production and the IL-4R-STAT6 signal pathway. Nature Immunol. 1, 515–520 (2000).
  Article CAS Google Scholar
• Ostrand-Rosenberg, S., Grusby, M. J. & Clements, V. K. STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma. J. Immunol. 165, 6015–6019 (2000).
  Article CAS PubMed Google Scholar
• Kacha, A. K., Fallarino, F., Markiewicz, M. A. & Gajewski, T. F. Spontaneous rejection of poorly immunogenic P1.HTR tumors by Stat6-deficient mice. J. Immunol. 165, 6024–6028 (2000).
  Article CAS PubMed Google Scholar
• Krummel, M. F. & Allison, J. P. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182, 459–465 (1995).
  Article CAS PubMed Google Scholar
• Lee, K. M. et al. Molecular basis of T cell inactivation by CTLA-4. Science 282, 2263–2266 (1998).
  Article CAS PubMed Google Scholar
• Greenwald, R. J., Boussiotis, V. A., Lorsbach, R. B., Abbas, A. K. & Sharpe, A. H. CTLA-4 regulates induction of anergy in vivo. Immunity 14, 145–155 (2001).
  Article CAS PubMed Google Scholar
• Shrikant, P., Khoruts, A. & Mescher, M. F. CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell-and IL-2-dependent mechanism. Immunity 11, 483–493 (1999).
  Article CAS PubMed Google Scholar
• Leach, D. R., Krummel, M. F. & Allison, J. P. Enhancement of anitumor immunity by CTLA-4 blockade. Science 271, 1734–1736 (1996).
  Article CAS PubMed Google Scholar
• Sutmuller, R. P. M. et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative cytotoxic T lymphocyte responses. J. Exp. Med. 194, 823–832 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Liu, M. A. & Ulmer, J. B. Gene-based vaccines. Mol. Ther. 1, 497–500 (2000).
  Article CAS PubMed Google Scholar
• Gurunathan, S., Klinman, D. M. & Seder, R. A. DNA vaccines: immunology, application, and optimization. Annu. Rev. Immunol. 18, 927–974 (2000).
  Article CAS PubMed Google Scholar
• Caley, I. J. et al. Venezuelan equine encephalitis virus vectors expressing HIV-1 proteins: vector design strategies for improved vaccine efficacy. Vaccine 17, 3124–3135 (1999).
  Article CAS PubMed Google Scholar
• Dubensky, T. W. Jr, Liu, M. A. & Ulmer, J. B. Delivery systems for gene-based vaccines. Mol. Med. 6, 723–732 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Leitner, W. W., Ying, H., Driver, D. A., Dubensky, T. W. & Restifo, N. P. Enhancement of tumor-specific immune response with plasmid DNA replicon vectors. Cancer Res. 60, 51–55 (2000).
  CAS PubMed PubMed Central Google Scholar
• Huang, Y., Kong, W. P. & Nabel, G. J. Human immunodeficiency virus type 1-specific immunity after genetic immunization is enhanced by modification of Gag and Pol expression. J. Virol. 75, 4947–4951 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Widera, G. et al. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J. Immunol. 164, 4635–4640 (2000).
  Article CAS PubMed Google Scholar
• Iwasaki, A., Torres, C. A. T., Ohashi, P. S., Robinson, H. L. & Barber, B. H. The dominant role of bone marrow-derived cells in CTL induction following plasmid DNA immunization at different sites. J. Immunol. 159, 11–14 (1997).
  CAS PubMed Google Scholar
• Porgador, A. et al. Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. J. Exp. Med. 188, 1075–1082 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Fu, T. M. et al. Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes. Mol. Med. 3, 362–371 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Tang, D., DeVit, M. & Johnston, S. A. Genetic immunization is a simple method for eliciting an immune response. Nature 356, 152–154 (1992).
  Article CAS PubMed Google Scholar
• Darji, A. et al. Oral somatic transgene vaccination using attenuated S. typhimurium. Cell 91, 765–775 (1997).
  Article CAS PubMed Google Scholar
• Woo, P. C., Wong, L. P., Zheng, B. J. & Yuen, K. Y. Unique immunogenicity of hepatitis B virus DNA vaccine presented by live-attenuated Salmonella typhimurium. Vaccine 19, 2945–2954 (2001).
  Article CAS PubMed Google Scholar
• Torres, C. A. T., Iwasaki, A., Barber, B. H. & Robinson, H. L. Differential dependence on target site tissue for gene gun and intramuscular DNA immunizations. J. Immunol. 158, 4529–4532 (1997).
  CAS PubMed Google Scholar
• Biragyn, A., Tani, K., Grimm, M. C., Weeks, S. & Kwak, L. W. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nature Biotechnol. 17, 253–258 (1999).
  Article CAS Google Scholar
• Klinman, D. M., Yi, A. K., Beaucage, S. L., Conover, J. & Krieg, A. M. CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc. Natl Acad. Sci. USA 93, 2879–2883 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Wang, R. et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 282, 476–480 (1998).
  Article CAS PubMed Google Scholar
• Hanke, T., Schneider, J., Gilbert, S. C., Hill, A. V. S. & McMichael, A. DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: immunogenicity in mice. Vaccine 16, 426–435 (1998).
  Article CAS PubMed Google Scholar
• Thomson, S. A. et al. Targeting a polyepitope protein incorporating multiple class II-restricted viral epitopes to the secretory/endocytic pathway facilitates immune recognition by CD4+ cytotoxic T lymphocytes: a novel approach to vaccine design. J. Virol. 72, 2246–2252 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Velders, M. P. et al. Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine. J. Immunol. 166, 5366–5373 (2001).
  Article CAS PubMed Google Scholar
• Moss, B. Vaccinia virus: a tool for research and vaccine development. Science 252, 1662–1667 (1991).
  Article CAS PubMed Google Scholar
• Sullivan, N. J., Sanchez, A., Rollin, P. E., Yang, Z. Y. & Nabel, G. J. Development of a preventive vaccine for Ebola virus infection in primates. Nature 408, 605–609 (2000).
  Article CAS PubMed Google Scholar
• Hanke, T. et al. Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. Vaccine 16, 439–445 (1998).
  Article CAS PubMed Google Scholar
• Kent, S. J. et al. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. J. Virol. 72, 10180–10188 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Amara, R. R. et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292, 69–74 (2001).
  Article CAS PubMed Google Scholar
• Scheerlinck, J. Y. et al. The immune response to a DNA vaccine can be modulated by co-delivery of cytokine genes using a DNA prime-protein boost strategy. Vaccine 19, 4053–4060 (2001).
  Article CAS PubMed Google Scholar
• Billaut-Mulot, O., Idziorek, T., Loyens, M., Capron, A. & Bahr, G. M. Modulation of cellular and humoral immune responses to a multiepitopic HIV-1 DNA vaccine by interleukin-18 DNA immunization/viral protein boost. Vaccine 19, 2803–2811 (2001).
  Article CAS PubMed Google Scholar
• Boyer, J. D. et al. Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of β-chemokines. J. Infect. Dis. 181, 476–483 (2000).
  Article CAS PubMed Google Scholar
• Banchereau, J. & Steinman, R. M. Dendritic cells and the control of immunity. Nature 392, 245–252 (1998).
  Article CAS PubMed Google Scholar
• Sigal, L. J. & Rock, K. L. Bone marrow-derived antigen-presenting cells are required for the generation of cytotoxic T lymphocyte responses to viruses and use transporter associated with antigen presentation (TAP)-dependent and- independent pathways of antigen presentation. J. Exp. Med. 192, 1143–1150 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Lenz, L. L., Butz, E. A. & Bevan, M. J. Requirements for bone marrow-derived antigen-presenting cells in priming cytotoxic T cell responses to intracellular pathogens. J. Exp. Med. 192, 1135–1142 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Gabrilovich, D. I. et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 2, 1096–1103 (1996); erratum 2, 1267 (1996). | PubMed |
  Article CAS PubMed Google Scholar
• Shearer, G. M. HIV-induced immunopathogenesis. Immunity 9, 587–593 (1998).
  Article CAS PubMed Google Scholar
• Harty, J. T. & Bevan, M. J. CD8+ T cells specific for a single nonamer epitope of Listeria monocytogenes are protective in vivo. J. Exp. Med. 175, 1531–1538 (1992).
  Article CAS PubMed Google Scholar
• Takahashi, H., Nakagawa, Y., Yokomuro, K. & Berzofsky, J. A. Induction of CD8+ CTL by immunization with syngeneic irradiated HIV-1 envelope derived peptide-pulsed dendritic cells. Int. Immunol. 5, 849–857 (1993).
  Article CAS PubMed Google Scholar
• Gabrilovich, D. I., Nadaf, S., Corak, J., Berzofsky, J. A. & Carbone, D. P. Dendritic cells in anti-tumor immune reponses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice are effective antigen carriers in the therapy of established tumors. Cell. Immunol. 170, 111–119 (1996).
  Article CAS PubMed Google Scholar
• Zitvogel, L. et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med. 183, 87–97 (1996).
  Article CAS PubMed Google Scholar
• Paglia, P., Chiodoni, C., Rodolfo, M. & Colombo, M. P. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med. 183, 317–322 (1996).
  Article CAS PubMed Google Scholar
• Labeur, M. S. et al. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J. Immunol. 162, 168–175 (1999).
  CAS PubMed Google Scholar
• Mackey, M. F. et al. Dendritic cells require maturation via CD40 to generate protective antitumor immunity. J. Immunol. 161, 2094–2098 (1998).
  CAS PubMed Google Scholar
• Diehl, L. et al. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nature Med. 5, 774–779 (1999).
  Article CAS PubMed Google Scholar
• Dhodapkar, M. V. et al. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J. Clin. Invest. 104, 173–180 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Dhodapkar, M. V., Krasovsky, J., Steinman, R. M. & Bhardwaj, N. Mature dendritic cells boost functionally superior CD8+ T-cell in humans without foreign helper epitopes. J. Clin. Invest. 105, R9–R14 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Mueller, D. L., Jenkins, M. K. & Schwartz, R. H. Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu. Rev. Immunol. 7, 445–480 (1989).
  Article CAS PubMed Google Scholar
• Roncarolo, M. G., Levings, M. K. & Traversari, C. Differentiation of T regulatory cells by immature dendritic cells. J. Exp. Med. 193, F5–F9 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Shirai, M. et al. Helper–CTL determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs. J. Immunol. 152, 549–556 (1994).
  CAS PubMed Google Scholar
• Ridge, J. P., Di Rosa, F. & Matzinger, P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393, 474–478 (1998).
  Article CAS PubMed Google Scholar
• Bennett, S. R. M. et al. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393, 478–480 (1998).
  Article CAS PubMed Google Scholar
• Schoenberger, S. P., Toes, R. E. M., van der Voort, E. I. H., Offringa, R. & Melief, C. J. M. T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions. Nature 393, 480–483 (1998).
  Article CAS PubMed Google Scholar
• Pulendran, B., Banchereau, J., Maraskovsky, E. & Maliszewski, C. Modulating the immune response with dendritic cells and their growth factors. Trends Immunol. 22, 41–47 (2001).
  Article CAS PubMed Google Scholar
• Banchereau, J. et al. Immunobiology of dendritic cells. Annu. Rev. Immunol. 18, 767–811 (2000).
  Article CAS PubMed Google Scholar
• Moser, M. & Murphy, K. M. Dendritic cell regulation of TH1-TH2 development. Nature Immunol. 1, 199–205 (2000).
  Article CAS Google Scholar
• Albert, M. L., Sauter, B. & Bhardwaj, N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392, 86–89 (1998).
  Article CAS PubMed Google Scholar
• Berard, F. et al. Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J. Exp. Med. 192, 1535–1544 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Engelmayer, J. et al. Mature dendritic cells infected with canarypox virus elicit strong anti- human immunodeficiency virus CD8+ and CD4+ T-cell responses from chronically infected individuals. J. Virol. 75, 2142–2153 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Mitchell, D. A. & Nair, S. K. RNA-transfected dendritic cells in cancer immunotherapy. J. Clin. Invest. 106, 1065–1069 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Boczkowski, D., Nair, S. K., Nam, J. H., Lyerly, H. K. & Gilboa, E. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res. 60, 1028–1034 (2000).
  CAS PubMed Google Scholar
• Sallusto, F. & Lanzavecchia, A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J. Exp. Med. 179, 1109–1118 (1994).
  Article CAS PubMed Google Scholar
• Thurner, B. et al. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J. Immunol. Methods 223, 1–15 (1999).
  Article CAS PubMed Google Scholar
• Mosca, P. J. et al. A subset of human monocyte-derived dendritic cells expresses high levels of interleukin-12 in response to combined CD40 ligand and interferon-γ treatment. Blood 96, 3499–3504 (2000).
  Article CAS PubMed Google Scholar
• Fong, L. & Engleman, E. G. Dendritic cells in cancer immunotherapy. Annu. Rev. Immunol. 18, 245–273 (2000).
  Article CAS PubMed Google Scholar
• Wong, E. C. C. et al. Development of a clinical-scale method for generation of dendritic cells from PBMC for use in cancer immunotherapy. Cytotherapy 3, 19–29 (2001).
  Article CAS PubMed Google Scholar
• Mulé, J. J. Dendritic cells: at the clinical crossroads. J. Clin. Invest. 105, 707–708 (2000).
  Article PubMed PubMed Central Google Scholar
• Dallal, R. M. & Lotze, M. T. The dendritic cell and human cancer vaccines. Curr. Opin. Immunol. 12, 583–588 (2000).
  Article CAS PubMed Google Scholar
• Thurner, B. et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 190, 1669–1678 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Nestle, F. O. et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Med. 4, 328–332 (1998).
  Article CAS PubMed Google Scholar
• Weber, J. S. & Aparicio, A. Novel immunologic approaches to the management of malignant melanoma. Curr. Opin. Oncol. 13, 124–128 (2001).
  Article CAS PubMed Google Scholar
• Hsu, F. J. et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med. 2, 52–58 (1996).
  Article CAS PubMed Google Scholar
• Liso, A. et al. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. Biol. Blood Marrow Transplant. 6, 621–627 (2000).
  Article CAS PubMed Google Scholar
• Pulendran, B. et al. Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo. J. Immunol. 165, 566–572 (2000).
  Article CAS PubMed Google Scholar
• Boyer, J. D. et al. HIV-1 DNA vaccines and chemokines. Vaccine 17 (Suppl. 2), S53–S64 (1999).
  Article CAS PubMed Google Scholar
• Matsui, S. et al. A model for CD8+ CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL. J. Immunol. 163, 184–193 (1999).
  CAS PubMed Google Scholar
• Ohodapkar, M. V., Steinman, R. M., Krasovsky, J., Munz, C. & Bhardwaj, N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J. Exp. Med. 193, 233–238 (2001).
  Article Google Scholar